Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain

Journal of Comparative Neurology

Volumn 479, Issue 4, 2004, Pages 410-423

  Hawes, Jessica J ^a   Picciotto, Marina R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopaminergic; Galanin; Galanin receptor; Noradrenergic; Tyrosine hydroxylase

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GALANIN; TYROSINE 3 MONOOXYGENASE;

AMYGDALOID NUCLEUS; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; CATECHOLAMINE NERVE CELL; CEREBELLUM; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DRUG WITHDRAWAL; HIPPOCAMPUS; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOCUS CERULEUS; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEUS ACCUMBENS; OLFACTORY BULB; PERIAQUEDUCTAL GRAY MATTER; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SPINAL CORD; SUBSTANTIA NIGRA; TEGMENTUM; WESTERN BLOTTING;

ANIMALS; BRAIN; CATECHOLAMINES; GALANIN; IMMUNOHISTOCHEMISTRY; LOCUS COERULEUS; MICE; NEURAL PATHWAYS; NEURONS; NUCLEUS ACCUMBENS; OPIOID-RELATED DISORDERS; RECEPTOR, GALANIN, TYPE 1; RECEPTOR, GALANIN, TYPE 2; RECEPTOR, GALANIN, TYPE 3; RECEPTORS, GALANIN; REWARD; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 7544243900     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.20329     Document Type: Article

References (24)

1. Branchek T, Smith KE, Walker MW. 1998. Molecular biology and pharmacology of galanin receptors. Ann N Y Acad Sci 863:94-107.
2. Branchek TA, Smith KE, Gerald C, Walker MW. 2000. Galanin receptor subtypes. Trends Pharmacol Sci 21:109-117.
3. Burgevin MC, Loquet I, Quarteronet D, Habert-Ortoli E. 1995. Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor. J Mol Neurosci 6:33-41.
4. Crawley JN, Mufson EJ, Hohmann JG, Teklemichael D, Steiner RA, Holmberg K, Xu ZQ, Blakeman KH, Xu XJ, Wiesenfeld-Hallin Z, Bartfai T, Hokfelt T. 2002. Galanin overexpressing transgenic mice. Neuropeptides 36:145-156.
5. Hohmann JG, Jureus A, Teklemichael DN, Matsumoto AM, Clifton DK, Steiner RA. 2003. Distribution and regulation of galanin receptor 1 messenger RNA in the forebrain of wild type and galanin-transgenic mice. Neuroscience 117:105-117.
6. Karelson E, Langel U. 1998. Galaninergic signalling and adenylate cyclase. Neuropeptides 32:197-210.
7. Kolakowski LF Jr, O'Neill GP, Howard AD, Broussard SR, Sullivan KA, Feighner SD, Sawzdargo M, Nguyen T, Kargman S, Shiao LL, Hreniuk DL, Tan CP, Evans J, Abramovitz M, Chateauneuf A, Coulombe N, Ng G, Johnson MP, Tharian A, Khoshbouei H, George SR, Smith RG, O'Dowd BF. 1998. Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J Neurochem 71:2239-2251.
8. Mennicken F, Hoffert C, Pelletier M, Ahmad S, O'Donnell D. 2002. Restricted distribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system. J Chem Neuroanat 24:257-268.
9. Merchenthaler I, Lopez FJ, Negro-Vilar A. 1993. Anatomy and physiology of central galanin-containing pathways. Prog Neurobiol 40:711-769.
10. O'Donnell D, Ahmad S, Wahlestedt C, Walker P. 1999. Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1. J Comp Neurol 409:469-481.
11. Parker EM, Izzarelli DG, Nowak HP, Mahle CD, Iben LG, Wang J, Goldstein ME. 1995. Cloning and characterization of the rat GALR1 galanin receptor from Rin14B insulinoma cells. Brain Res Mol Brain Res 34:179-189.
12. Paxinos G, Franklin KBJ. 2001. The mouse brain in stereotaxic coordinates. London: Academic Press.
13. Shen PJ, Larm JA, Gundlach AL. 2003. Expression and plasticity of galanin systems in cortical neurons, oligodendrocyte progenitors and proliferative zones in normal brain and after spreading depression. Eur J Neurosci 18:1362-1376.
14. Smith KE, Walker MW, Artymyshyn R, Bard J, Borowsky B, Tamm JA, Yao WJ, Vaysse PJ, Branchek TA, Gerald C, Jones KA. 1998. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem 273:23321-23326.
15. Tsuda K, Tsuda S, Nishio I, Masuyama Y, Goldstein M. 1998. Effects of galanin on dopamine release in the central nervous system of normotensive and spontaneously hypertensive rats. Am J Hypertens 11:1475-1479.
16. Wang S, Hashemi T, He C, Strader C, Bayne M. 1997a. Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol 52:337-343.
17. Wang S, He C, Hashemi T, Bayne M. 1997b. Cloning and expressional characterization of a novel galanin receptor. Identification of different pharmacophores within galanin for the three galanin receptor subtypes. J Biol Chem 272:31949-31952.
18. Wang S, He C, Maguire MT, Clemmons AL, Burrier RE, Guzzi MF, Strader CD, Parker EM, Bayne ML. 1997c. Genomic organization and functional characterization of the mouse GalR1 galanin receptor. FEBS Lett 411:225-230.
19. Wang S, Hashemi T, Fried S, Clemmons AL, Hawes BE. 1998. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 37:6711-6717.
20. Waters SM, Krause JE. 2000. Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience 95:265-271.
21. Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G, Gudermann T. 2000. The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene 19:4199-4209.
22. Zachariou V, Parikh K, Picciotto MR. 1999. Centrally administered galanin blocks morphine place preference in the mouse. Brain Res 831:33-42.
23. Zachariou V, Thome J, Parikh K, Picciotto MR. 2000. Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal. Neuropsychopharmacology 23:127-137.
24. Zachariou V, Brunzell DH, Hawes J, Stedman DR, Bartfai T, Steiner RA, Wynick D, Langel U, Picciotto MR. 2003. The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proc Natl Acad Sci U S A 100:9028-9033.